Team Portfolio Raise Champions Essays

F4/Ysios Capital/Activity

Ysios Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

3 milestones· JUL 2026 – SEP 2026Show all

Milestone

Ona Therapeutics advanced to a clinical-stage company and appointed Aleix Prat, MD, PhD, as Chief Medical Officer.

Ona Therapeutics

Ona Therapeutics Ysios Capital

Ysios Capital | Activity | F4

ysioscapital.comSEP 24, 2026

SEP 24, 2026

Milestone

Portfolio company Anaconda Biomed secured $56 million in financing from new and existing investors.

Anaconda Biomed

Anaconda Biomed Ysios Capital

ysioscapital.comSEP 23, 2026

SEP 23, 2026

Milestone

Portfolio company Xeltis raised an additional €20.5M to advance its aXess vascular access device toward FDA approval and US commercial launch.

Xeltis

Xeltis Ysios Capital

ysioscapital.comJUL 28, 2026

ysioscapital.com

ysioscapital.com

JUL 28, 2026

Essay

Published a review of the prior eighteen months, combining strong portfolio execution with expansion of the investment platform.

Ysios Capital 2025 / H1 2026 Review

ysioscapital.comJUL 28, 2026

JUL 28, 2026

Milestone

Portfolio company Minoryx's NEZGLYAL (leriglitazone) received a positive CHMP opinion for treatment of cerebral Adrenoleukodystrophy.

Minoryx Therapeutics

Minoryx Therapeutics Ysios Capital

ysioscapital.comJUL 24, 2026

JUL 24, 2026

Exit

Portfolio company Memo Therapeutics was acquired by Ipsen, adding a first-in-class BK polyomavirus antibody to Ipsen's rare disease pipeline.

Memo Therapeutics

Memo Therapeutics Ysios Capital

ysioscapital.comJUL 22, 2026

ysioscapital.com

JUL 22, 2026

Milestone

Portfolio company Aura Biosciences appointed Jeremy Bender, PhD, MBA, to its Board of Directors.

Aura Biosciences

Aura Biosciences Ysios Capital

ysioscapital.comJUL 8, 2026

JUL 8, 2026

New Fund

Launched InceptionBio, a €100M fund to drive biotech company creation with a strong focus on Spain.

InceptionBio

ysioscapital.comMAR 27, 2026

MAR 27, 2026